- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11.25 | IDL Diagnostics AB: IDL Diagnostics AB (publ) Interim Report January 1st to September 30th, 2025 | 171 | GlobeNewswire (Europe) | A word from the CEO"We are pleased to report continued progress for our UBC bladder cancer test during the past quarter. UBC tests continue to show steady growth, reflecting the strength of our products... ► Artikel lesen | |
| 10.11.25 | IDL Diagnostics AB: First commercial order from Japanese partner secured for the Chinese market | 116 | GlobeNewswire (Europe) | IDL Diagnostics has secured its first commercial order for TPS CLIA from its Japanese partner, a leading global Japanese IVD company, for deployment within the Chinese market.
"I am happy to announce... ► Artikel lesen | |
| 29.09.25 | IDL Diagnostics AB: IDL Diagnostics secures patent approval in Hong Kong for the use of TK1 protein in respiratory infections | 219 | GlobeNewswire (Europe) | IDL Diagnosticsl AB (publ) is pleased to announce that its patent application (HK40055647) for the novel use of thymidine kinase 1 (TK1) protein in detecting and categorizing respiratory infections... ► Artikel lesen | |
| 21.08.25 | IDL Diagnostics AB: IDL Diagnostics AB (publ) Interim Report January 1st to June 30th, 2025 | 153 | GlobeNewswire (Europe) | A word from the CEO"In the second quarter, we have focused on creating a stable foundation to broaden and develop our sales, both in existing and upcoming new markets. A crucial factor for success is... ► Artikel lesen | |
| 12.08.25 | IDL Diagnostics AB: New Study Highlights Potential of IDL diagnostics biomarkers TK1 and TPS in Guiding Therapy for Advanced Prostate Cancer | 406 | GlobeNewswire (Europe) | A new scientific study that has been accepted for publication in Urologic Oncology: Seminars and Original Investigations demonstrates a useful clinical application of two IDL Diagnostics blood biomarkers:... ► Artikel lesen | |
| IDL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 27.05.25 | IDL Diagnostics AB: AroCell changes name to IDL Diagnostics AB | 278 | GlobeNewswire (Europe) | AroCell AB (publ) today announces that the company will change its name to IDL Diagnostics AB in accordance with a resolution made at AroCell's Annual General Meeting on 15 May 2025. On 27 May, trading... ► Artikel lesen | |
| 26.05.25 | Change of company name and ticker for AroCell AB | 372 | GlobeNewswire | As from May 27, 2025, AroCell AB will change company name to IDL Diagnostics AB (publ).
Old company name: AroCell AB
New company name: IDL Diagnostics AB (publ)
Old ticker: AROC
New... ► Artikel lesen | |
| 15.05.25 | AroCell AB: Report from AroCell's Annual General Meeting 2025 | 334 | GlobeNewswire (Europe) | (Available in Swedish only)
Nedan redovisas de väsentliga beslut som fattades vid AroCells årsstämma tidigare idag den 15 maj 2025. Stämman hölls i AroCells lokaler i Stockholm samt genom poströstning.... ► Artikel lesen | |
| 07.05.25 | AroCell AB: AroCell AB (publ) Interim Report January 1st to March 31st, 2025 | 258 | GlobeNewswire (Europe) | A word from the CEO"AroCell experienced a high level of activity during the first quarter of the year. Sales continue to grow in both oncology and bacteriology and order intake is also showing a continued... ► Artikel lesen | |
| 11.04.25 | AroCell AB: AroCell's board of directors proposes to the AGM that the parent company change its name to IDL Diagnostics AB | 202 | GlobeNewswire (Europe) | The board proposes to the annual general meeting (AGM) that AroCell AB changes its name to IDL Diagnostics AB. The main purpose of the name change is to create a stronger connection to the diagnostics... ► Artikel lesen | |
| 19.02.25 | AroCell AB: AroCell AB (publ) Interim Report January 1st to December 31st, 2024 | 248 | GlobeNewswire (Europe) | A word from the CEO" It is with great pleasure that I present this year's results. The year has been characterized by continuous and strong sales growth. We have increased our sales by over 33% compared... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 104,72 | -0,38 % | GSK: Erfolg in Hepatitis B - wird Gilead nun abgehängt? | GlaxoSmithKline hat positive Ergebnisse aus den beiden entscheidenden Phase-3-Studien seines experimentellen Medikaments Bepirovirsen zur Behandlung von chronischer Hepatitis B vorgelegt. Noch im laufenden... ► Artikel lesen | |
| TILRAY BRANDS | 8,086 | +1,35 % | Cannabis-Aktie Tilray Brands mit Kurssprung - das ist der Grund | Die Aktie des Cannabis-Unternehmens Tilray Brands hat in den vergangenen Monaten bereits mehrere deutliche Lebenszeichen von sich gegeben. Zuletzt ging es im Dezember kräftig nach oben, nachdem US-Präsident... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 393,05 | -0,44 % | AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations | ||
| DIGICANN VENTURES | 0,001 | -95,45 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 13,700 | +0,74 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) | Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia... ► Artikel lesen | |
| BAYER | 39,555 | -0,39 % | DAX: Nächster Angriff auf die 25.000 Punkte? Siemens, Bayer, Redcare und Nordex im Blickpunkt | Der DAX dürfte am Mittwoch weiter mit dem Sprung über die 25.000-Punkte-Marke liebäugeln. Der Broker IG taxierte den deutschen Leitindex zwei Stunden vor dem Auftakt 0,25 Prozent im Plus auf 24.955... ► Artikel lesen | |
| NOVO NORDISK | 51,45 | +0,06 % | Novo Nordisk: Aktie haussiert weiter | Der Start in das neue Börsenjahr 2026 ist der Aktie von Novo Nordisk absolut geglückt. Im heutigen Handel legt die Aktie des dänischen Pharmariesen erneut kräftig zu. Aktuell beläuft sich das Plus des... ► Artikel lesen | |
| HARROW | 47,840 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,510 | 0,00 % | Faruqi & Faruqi LLP: INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics | Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf... ► Artikel lesen | |
| MERCK KGAA | 129,75 | -1,14 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 120 auf 130 Euro angehoben und die Einstufung auf "Equal Weight" belassen. Für den Pharma- und Spezialchemiekonzern... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 88,12 | +1,58 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 15,470 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| LB PHARMACEUTICALS | 19,030 | -8,20 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| LIPOCINE | 9,030 | 0,00 % | Lipocine Inc.: Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | Company on track to report topline results early in the second quarter of 2026
Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,960 | -3,92 % | Milestone Pharmaceuticals Inc. - 8-K, Current Report |
IDL DIAGNOSTICS AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,019 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IDL DIAGNOSTICS AB finden Sie auf Wallstreet Online.